Technology area: Biotechnology & Pharmaceuticals
23 pending office actions • 12 art units • 20 examiners • 0 of 23 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Foundation Medicine Inc. has 24 pending office actions in Biotechnology & Pharmaceuticals. The matters span 21 distinct examiners and 12 distinct art units, showing broad examiner distribution alongside repeated activity within some technical groups. The portfolio therefore requires both matter-specific examiner analysis and art-unit-level coordination.
KIM, YOUNG J is the busiest examiner, with 2 pending matters. This is a limited concentration compared with the overall pending workload, so the supplied data does not support treating one examiner as representative of the portfolio. Counsel should align recurring technical positions while preserving responses tailored to each examination record.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (4%) |
| §101 + other | 13 (57%) |
| §103 only | 1 (4%) |
| §102 only | 1 (4%) |
| §112 only | 2 (9%) |
| Double-patenting only | 1 (4%) |
| Multi-statute (no §101) | 4 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YOUNG J | 2 | 64.8% | +18.2% |
| VANNI, GEORGE STEVEN | 2 | 66.8% | +25.2% |
| POHNERT, STEVEN C | 2 | 12.5% | +18.2% |
| KALLAL, ROBERT JAMES | 1 | 59.4% | +31.2% |
| MAHROUKA, WASSIM | 1 | 86.2% | +6.2% |
| GARTLAND, SCOTT D | 1 | 10.9% | +12.2% |
| KOROMA, SORIE IBRAHIM | 1 | 50.0% | +0.0% |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
| DAUNER, JOSEPH G | 1 | 57.0% | +35.3% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18975942 | METHODS AND SYSTEMS FOR CHARACTERIZING AND TREATING A DISEASE | GARTLAND, SCOTT D | 5d |
| 17772451 | SYSTEMS AND METHODS FOR NUCLEIC ACID SEQUENCING ASSEMBLY ASSOCIATED WITH IN SILICO GENOMIC VARIANT IDENTIFICATION | SABOUR, GHAZAL | 29d |
| 19020349 | METHODS AND SYSTEMS FOR DETERMINING CIRCULATING TUMOR DNA FRACTION IN A PATIENT SAMPLE | KALLAL, ROBERT JAMES | — |
| 18999712 | METHODS AND SYSTEMS FOR PREDICTING GENOTYPIC CALLS FROM WHOLE-SLIDE IMAGES | MAHROUKA, WASSIM | — |
| 18910993 | SYSTEMS AND METHODS FOR PREDICTING SLIDE-LEVEL CLASS LABELS FOR A WHOLE-SLIDE IMAGE | KOROMA, SORIE IBRAHIM | — |
| 18722508 | DETECTION OF GENETIC AND EPIGENETIC INFORMATION IN A SINGLE WORKFLOW | KIM, YOUNG J | — |
| 18709782 | FRAGMENT CONSENSUS METHODS FOR ULTRASENSITIVE DETECTION OF ABERRANT METHYLATION | CASH, KAILEY ELIZABETH | — |
| 18702751 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | DAUNER, JOSEPH G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18975942 | METHODS AND SYSTEMS FOR CHARACTERIZING AND TREATING A DISEASE | GARTLAND, SCOTT D | 5d |
| 19020349 | METHODS AND SYSTEMS FOR DETERMINING CIRCULATING TUMOR DNA FRACTION IN A PATIENT SAMPLE | KALLAL, ROBERT JAMES | — |
| 18722508 | DETECTION OF GENETIC AND EPIGENETIC INFORMATION IN A SINGLE WORKFLOW | KIM, YOUNG J | — |
| 18709782 | FRAGMENT CONSENSUS METHODS FOR ULTRASENSITIVE DETECTION OF ABERRANT METHYLATION | CASH, KAILEY ELIZABETH | — |
| 18702751 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | DAUNER, JOSEPH G | — |
| 18699569 | CD274 REARRANGEMENTS AS PREDICTORS OF RESPONSE TO IMMUNE CHECKPOINT INHIBITOR THERAPY | GOLDBERG, JEANINE ANNE | — |
| 18689774 | GENE FUSIONS IN SARCOMA | KIM, YOUNG J | — |
| 18274675 | METHODS AND SYSTEMS FOR CHARACTERIZING AND TREATING COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA | VANNI, GEORGE STEVEN | — |
| Art Unit | Apps |
|---|---|
| 1686 | 4 |
| 1683 | 3 |
| 1682 | 3 |
| 1681 | 2 |
| 1685 | 1 |
| 2665 | 1 |
| 3685 | 1 |
| 2662 | 1 |
| 1684 | 1 |
| 3681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19020349 | METHODS AND SYSTEMS FOR DETERMINING CIRCULATING TUMOR DNA FRACTION IN A PATIENT SAMPLE | KALLAL, ROBERT JAMES | 1685 | §101 | Non-Final OA | — | Pending | Jan 14, 2025 |
| 18999712 | METHODS AND SYSTEMS FOR PREDICTING GENOTYPIC CALLS FROM WHOLE-SLIDE IMAGES | MAHROUKA, WASSIM | 2665 | §103§112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18975942 | METHODS AND SYSTEMS FOR CHARACTERIZING AND TREATING A DISEASE | GARTLAND, SCOTT D | 3685 | §101§102§103§112 | Final Rejection | 5d | Pending | Dec 10, 2024 |
| 18910993 | SYSTEMS AND METHODS FOR PREDICTING SLIDE-LEVEL CLASS LABELS FOR A WHOLE-SLIDE IMAGE | KOROMA, SORIE IBRAHIM | 2662 | §103§112 | Non-Final OA | — | Pending | Oct 09, 2024 |
| 18722508 | DETECTION OF GENETIC AND EPIGENETIC INFORMATION IN A SINGLE WORKFLOW | KIM, YOUNG J | 1681 | §102§103§112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18709782 | FRAGMENT CONSENSUS METHODS FOR ULTRASENSITIVE DETECTION OF ABERRANT METHYLATION | CASH, KAILEY ELIZABETH | 1683 | §101§102§103§112 | Non-Final OA | — | Pending | May 13, 2024 |
| 18702751 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | DAUNER, JOSEPH G | — | §101§103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18699569 | CD274 REARRANGEMENTS AS PREDICTORS OF RESPONSE TO IMMUNE CHECKPOINT INHIBITOR THERAPY | GOLDBERG, JEANINE ANNE | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18607277 | MULTIGENE ANALYSIS OF TUMOR SAMPLES | LAFAVE, ELIZABETH ROSE | 1684 | §103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18689774 | GENE FUSIONS IN SARCOMA | KIM, YOUNG J | 1681 | §112 | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18579296 | METHODS AND SYSTEMS FOR DETERMINING MICROSATELLITE INSTABILITY | SKIBINSKY, ANNA | — | §101§103 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18570006 | METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE OF IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER | GRAY, JESSICA | 1682 | §101§103§112 | Final Rejection | — | Pending | Dec 13, 2023 |
| 18290138 | CD274 MUTATIONS FOR CANCER TREATMENT | MYERS, CARLA J | 1682 | §102§103§112Other | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18287438 | METHODS AND SYSTEMS FOR GENE ALTERATION PREDICTION FROM PATHOLOGY SLIDE IMAGES | VASSELL, MEREDITH ABBOTT | — | §101§102§103§112Other | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18274675 | METHODS AND SYSTEMS FOR CHARACTERIZING AND TREATING COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA | VANNI, GEORGE STEVEN | 1686 | §101§103 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18267701 | IGH REARRANGEMENTS AND USES THEREOF | POHNERT, STEVEN C | 1683 | §101§103§112 | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18027826 | METHODS FOR DETERMINING VARIANT FREQUENCY AND MONITORING DISEASE PROGRESSION | NEWTON, CHAD A | 3681 | §102 | Final Rejection | 12d | Pending | Mar 22, 2023 |
| 18008410 | METHODS AND SYSTEMS FOR DISTINGUISHING SOMATIC GENOMIC SEQUENCES FROM GERMLINE GENOMIC SEQUENCES | PLAYER, ROBERT AUSTIN | 1686 | §101§103DP | Final Rejection | — | Pending | Dec 05, 2022 |
| 17899470 | SYSTEMS AND METHODS FOR CLASSIFYING AND TREATING HOMOLOGOUS REPAIR DEFICIENCY CANCERS | LEVERETT, MARY CHANG | 1687 | §101§103Other | Final Rejection | — | Pending | Aug 30, 2022 |
| 17802436 | MITIGATION OF STATISTICAL BIAS IN GENETIC SAMPLING | POHNERT, STEVEN C | 1683 | §101§112 | Final Rejection | — | Pending | Aug 25, 2022 |
| 17772451 | SYSTEMS AND METHODS FOR NUCLEIC ACID SEQUENCING ASSEMBLY ASSOCIATED WITH IN SILICO GENOMIC VARIANT IDENTIFICATION | SABOUR, GHAZAL | 1686 | §101§103§112 | Final Rejection | 29d | Pending | Apr 27, 2022 |
| 17535492 | METHODS OF TREATING UROTHELIAL CARCINOMA | GODDARD, LAURA B | 1642 | §112 | Final Rejection | 8d | Pending | Nov 24, 2021 |
| 17612966 | SYSTEMS AND METHODS FOR EVALUATING TUMOR FRACTION | VANNI, GEORGE STEVEN | 1686 | DP | Non-Final OA | — | Pending | Nov 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFoundation Medicine Inc. has 23 pending office actions as of October 2026, spread across 12 art units and 20 examiners.
Young J Kim has the most, with 2 of Foundation Medicine Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
